Charles Schwab Investment Management Inc. Has $23.22 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Charles Schwab Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,167,743 shares of the biopharmaceutical company’s stock after purchasing an additional 50,804 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.98% of Catalyst Pharmaceuticals worth $23,215,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of CPRX. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $50,000. CWM LLC increased its stake in shares of Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at about $70,000. Finally, SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at about $173,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Activity

In other news, Director Molly Harper sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Down 1.2 %

Shares of Catalyst Pharmaceuticals stock opened at $21.70 on Friday. The stock has a market cap of $2.59 billion, a P/E ratio of 18.39, a P/E/G ratio of 3.31 and a beta of 0.75. The business’s 50 day moving average is $21.40 and its 200-day moving average is $18.91. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.00 and a 12-month high of $24.27.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CPRX. Citigroup raised their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Truist Financial boosted their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $31.14.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.